Saad Mark E

Director Saad Mark E sold 37,577 shares of AXSM for $6,206,968.86, reducing holdings by 79.0%, as stock rallies 48.5% in 90 days.

Saad Mark E (Director) executed two separate sales totaling 37,577 shares at $165.18 on 2025-12-31, reducing his position from 47,579 shares to 10,002 shares—a 79.0% reduction. The timing is notable: the stock is up +48.5% over the trailing 90 days and currently at $178.69, 2.2% below its 52-week high. However, his prior sales at Axsome show a pattern of being poorly timed: his 2025-09-05 sale preceded a +18.4% 90-day gain, and his 2024-09-11 sale preceded a +8.2% 90-day gain; neither was well-timed (0 of 2 prior sells at this ticker had negative 90d returns). The company's fundamentals remain mixed—revenue grew +42.5% annually to $171.0M, but the company posted a net loss of $47.2M in the latest quarter and remains unprofitable on a full-year basis. The sale occurs into strength rather than weakness, and the director retains only 10,002 shares post-transaction.

Director Mark Saad sold 9,127 shares (47.7% of holdings) at $125.07; prior AXSM sale underperformed 90-day returns.

Saad Mark E, a director of Axsome Therapeutics, sold 9,127 shares on 2025-09-05 at $125.07, reducing his position from 19,129 shares to 10,002 shares. The stock has since risen 21.2% in 30 days and 11.8% in 90 days from the transaction date, placing the sale near the 52-week high of $137.75 (-9.1% from peak). Examining his prior transaction at AXSM (a sale on 2024-09-11), that trade was followed by a 90-day return of +8.2%—indicating the sale occurred before a stock rise, which is poorly-timed execution for a seller. His cross-ticker track record shows an average 90-day return of +8.2% after sells, with a well-timed rate of 0.00%, meaning none of his prior open-market sales have been followed by subsequent stock declines. The company remains unprofitable (net income $-47,973,000.00) despite strong revenue growth of +42.5%, presenting a contrasting operational backdrop to the director's asset reduction.

Director Saad sold 11,016 shares of AXSM at $91.31 on 2024-09-11; reduces holdings 52.4% while company posts $-79.3M net loss.

Director Saad Mark E executed a substantial sale of 11,016 shares at $91.31, reducing his holdings by 52.4% from 21,018 to 10,002 shares. The sale occurred when Axsome Therapeutics faces significant profitability challenges: the company reported net income of $-79,345,000.00 against quarterly revenue of $87,166,000.00, indicating the company was unprofitable over its most recent full fiscal year. The director's decision to liquidate more than half his position warrants investor attention given the company's negative earnings backdrop, though the stock has appreciated 7.2% over 30 days and 25.5% over 90 days. The transaction value of $1,005,870.96 represents a material reduction in the insider's committed stake at a company navigating substantial operational losses.